Drugs & Targets FDA grants RP1 BLA priority review for advanced melanoma January 24, 2025Vol.51 No.03
Guest Editorial FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials January 17, 2025Vol.51 No.02By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer
Drugs & Targets FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer January 17, 2025Vol.51 No.02
Drugs & Targets FDA approves acalabrutinib + bendamustine and rituximab for mantle cell lymphoma January 17, 2025Vol.51 No.02
Drugs & Targets FDA issues proposed rule to limit nicotine in cigarettes January 17, 2025Vol.51 No.02
Drugs & Targets FDA revokes authorization of Red No. 3 in food and ingested drugs January 17, 2025Vol.51 No.02
Drugs & Targets FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas January 17, 2025Vol.51 No.02
Conversation with The Cancer Letter After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency January 10, 2025Vol.51 No.01By Paul Goldberg
FreeTrials & Tribulations New colorectal cancer screening strategies must advance the standard of care January 10, 2025Vol.51 No.01By Paul J. Limburg
Drugs & Targets FDA issues draft guidance on including tissue biopsies in clinical trials January 10, 2025Vol.51 No.01
